Moderna book profit as its COVID-19 vaccine sales expectation altered


Fletcher, CC BY 4.0, via Wikimedia Commons Fletcher

Moderna Inc reported a profit of 19 cents per share on Thursday. This trashed their expectation of a gross loss. Due to their deferred COVID-19 vaccine supplies. 

They booked more revenue than in the first quarter of last year. This vaccine maker reported a profit of 19 cents per share. 

Moderna is also aware of the falling demand for COVID-19 vaccine sales. They are expecting a loss in COVID-19 vaccine sales next quarter. 

Moderna’s annual sales may go up as the new vaccination season begins. They have many contracts and upcoming contracts to be signed in the U.S. before the upcoming vaccination season.



Editor's Desk

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

WHO declares conclusion to COVID-19's emergency phase

Wed May 10 , 2023
Image by cromaconceptovisual from Pixabay 3 years after declaring COVID-19 as a pandemic, World Health Organization (WHO) declares the end of COVID-19’s emergency phase. They said COVID-19 is no longer a public health emergency of international concern. This decision was made by the COVID-19 emergency committee with Dr Tedros, the WHO director-general on […]

Related Articles